The biased apelin receptor agonist, MM07, reverses Sugen/hypoxia-induced pulmonary arterial hypertension as effectively as the endothelin antagonist macitentan
Introduction: Pulmonary arterial hypertension (PAH) is characterised by endothelial dysfunction and pathological vascular remodelling, resulting in the occlusion of pulmonary arteries and arterioles, right ventricular hypertrophy, and eventually fatal heart failure. Targeting the apelin receptor wit...
Saved in:
Main Authors: | Thomas L. Williams (Author), Duuamene Nyimanu (Author), Rhoda E. Kuc (Author), Richard Foster (Author), Robert C. Glen (Author), Janet J. Maguire (Author), Anthony P. Davenport (Author) |
---|---|
Format: | Book |
Published: |
Frontiers Media S.A.,
2024-04-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
The G Protein Biased Small Molecule Apelin Agonist CMF-019 is Disease Modifying in Endothelial Cell Apoptosis In Vitro and Induces Vasodilatation Without Desensitisation In Vivo
by: Cai Read, et al.
Published: (2021) -
The endothelin receptor antagonist macitentan for the treatment of pulmonary arterial hypertension: A cross‐species comparison of its cytochrome P450 induction pattern
by: Alexander Treiber, et al.
Published: (2020) -
Using extracellular matrix derived from sugen-chronic hypoxia lung tissue to study pulmonary arterial hypertension
by: Patrick A. Link, et al.
Published: (2023) -
Direct Delivery of MicroRNA96 to the Lungs Reduces Progression of Sugen/Hypoxia-Induced Pulmonary Hypertension in the Rat
by: Craig K. Docherty, et al.
Published: (2020) -
MicroRNA-212-5p, an anti-proliferative miRNA, attenuates hypoxia and sugen/hypoxia-induced pulmonary hypertension in rodents
by: Tianji Chen, et al.
Published: (2022)